Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

271.36
+4.671.75%
Pre-market: 270.68-0.6763-0.25%05:44 EDT
Volume:6.08M
Turnover:1.65B
Market Cap:479.60B
PE:76.66
High:274.94
Open:268.40
Low:266.89
Close:266.69
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.16
T/O Rate:0.34%
Dividend:6.83
Dividend Rate:2.52%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-80.81
PE(LYR):114.98

Loading ...

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Citi Keeps Their Hold Rating on AbbVie (ABBV)

TIPRANKS
·
Sep 29

AbbVie price target raised to $289 from $282 at BofA

TIPRANKS
·
Sep 29

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Quantum-Si (QSI)

TIPRANKS
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

TIPRANKS
·
Sep 28